SynteractHCR, a full-service, international contract research organization (CRO), is announcing that its Vice President for Global Medical and Regulatory Affairs, Dr. Martine Dehlinger-Kremer, has recently been appointed as the chair of the European Forum for Good Clinical Practice (EFGCP) Children’s Medicines Working Party. As such, Dehlinger-Kremer, is now also a member of the EFGCP Board.
Dehlinger-Kremer will work with the Co-Chair of the EFGCP Children’s Medicines Working Party, Dimitrios Athanasiou. Athanasiou is head of patient advocacy of Muscular Dystrophy Association Hellas (MDA Hellas) Greece; board member of United Parent Projects Muscular Dystrophy (UPPMD), the worldwide group of Duchenne Patient and Parent Organizations and the EFGCP and an EMA-nominated expert for DMD.
EFGCP is a non-profit organization established by and for individuals with a professional involvement in the conduct of biomedical research. Founded during a conference at the European Parliament in 1993 with the support of the European Commission, The EFGCP Children's Medicines Working Party facilitates multi-stakeholder discussion in Europe on best practices and standards in pediatric drug development needed for better medicines for children. Members include representatives from pharmaceutical companies, pediatricians and academia, regulatory authorities, patients' and parents' organizations and ethics committees.
Dr. Martine Dehlinger-Kremer draws on over 30 years experience in the clinical research industry and has contributed to the global development of numerous pharmaceutical products and devices, including participating in 100+ NDAs/MAAs. She is also chair of the EUCROF Pediatric Working Group, a member of Enpr-EMA working parties and has been a frequent speaker and session chair on clinical pediatric research at EUCROF European Conference on Clinical Research, EFGCP/DIA/EMA Better Medicines for Children Conference, PHARMIG/OKIDS Conference and others.
“Dr. Dehlinger-Kremer exemplifies our culture, at SynteractHCR, of dedication and collaboration to bring better medicines to market for patients,” said Wendel Barr, CEO of SynteractHCR. “We congratulate her on the addition of this exciting, new role as she continues to work with other leaders on the forefront of pediatric drug development.”
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005257/en/Business Wire
Last updated on: 09/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.